JAMA 2023 Jan 24
Sequential, Multiple Assignment, Randomized Trial Designs.
Related Questions
New answer by Medical Oncologist at The University of Texas, M.D. Anderson Cancer Center (April 2, 2024)
Practically all my patients with metastatic clear cell RCC will receive an mTOR inhibitor at some time during their treatment course unless they achieve durable CR with early ...